FDA regulatory timeline
2023 — 202619 EVENTS TRACKEDThe peptide regulatory landscape has shifted dramatically since 2023. This timeline tracks every major FDA action — Category 2 restrictions, warning letters, vendor shutdowns, GLP-1 shortage resolutions, compounding pharmacy deadlines, the 2026 Category 2 removals, and the PCAC review that follows them. Updated as events unfold.
FDA places 19 peptides in Category 2 of the interim 503A list
The FDA designates 19 widely used peptides as Category 2 substances on its interim Section 503A bulk drug substances list, citing significant safety risks including immunogenicity, manufacturing impurities and toxicity concerns, and insufficient human clinical data. The list includes BPC-157, TB-500, GHK-Cu, Semax, Epitalon, and others. Category 2 substances fall outside FDA enforcement discretion, so licensed compounding pharmacies can no longer legally prepare them. This action, taken under the Biden administration, is the origin of every restriction that follows.
FDA issues warning letters to peptide vendors
Summit Research Peptides, Prime Peptides, Xcel Peptides, and SwissChems receive FDA warning letters for selling unapproved new drugs. This signals escalation from Category 2 restrictions to active enforcement against the gray market.
FDA determines tirzepatide shortage resolved
The FDA removes tirzepatide from the drug shortage list, closing the basis on which compounding pharmacies had produced tirzepatide under shortage provisions. The Outsourcing Facilities Association sues days later, arguing the decision was arbitrary and capricious. FDA revisits the question and reaffirms resolution in a December 19, 2024 declaratory order, which sets the actual wind-down deadlines.
FDA ends interim category system for new substances
The FDA announces it will no longer categorize newly nominated bulk drug substances into interim categories. All new substances must complete the full review process before any compounding is permitted. This effectively closes the pipeline for adding new peptides to the legal compounding list.
FDA removes semaglutide from drug shortage list
With the semaglutide shortage officially resolved, compounders lose the legal basis for producing generic semaglutide. 503A pharmacies face an April 22 deadline; 503B facilities face a May 22 deadline to cease GLP-1 compounding.
Peptide Sciences shuts down
One of the largest and most established US peptide research chemical suppliers ceases operations. The closure follows escalating FDA enforcement and represents a major supply chain disruption for the research peptide market.
Tirzepatide compounding deadlines take effect
Following FDA's December 19, 2024 declaratory order reaffirming that the tirzepatide shortage was resolved, enforcement discretion ends: state-licensed 503A pharmacies had 60 calendar days, to February 18, 2025, and 503B outsourcing facilities had 90 days, to March 19, 2025. These are tirzepatide's deadlines specifically. Semaglutide's are later and separate, and the two are frequently and incorrectly reported as sharing one timeline.
503A pharmacy deadline for compounded semaglutide
State-licensed 503A compounding pharmacies must cease compounding semaglutide by this date, following FDA's February 2025 determination that the semaglutide shortage was resolved. Many clinics that relied on compounded GLP-1 agonists for weight-management patients lose their supply.
503B facility deadline for compounded semaglutide
Outsourcing facilities (503B) must cease compounding semaglutide one month after 503A pharmacies. With tirzepatide's equivalent deadline having passed on March 19, this closes the last remaining shortage-based pathway for compounded GLP-1 agonists.
FDA raids Amino Asylum warehouse
Federal agents raid Amino Asylum's warehouse operations in Tennessee/Kentucky. The site goes offline immediately and all operations cease. This is one of the first physical law enforcement raids on a peptide vendor, signaling a new level of enforcement intensity.
FDA issues 50+ warning letters to GLP-1 compounders
The FDA sends more than 50 warning letters to US and international compounders and manufacturers of GLP-1 receptor agonists. This mass enforcement action is unprecedented in scope for the peptide industry.
Multiple criminal prosecutions with $1.79M-$3M+ forfeitures
Federal prosecutors secure forfeitures ranging from $1.79 million to over $3 million in cases against peptide vendors. Criminal charges include distribution of unapproved new drugs, conspiracy, and money laundering.
RFK Jr. floats peptide reclassification on the Joe Rogan podcast
HHS Secretary Robert F. Kennedy Jr. says on The Joe Rogan Experience (episode 2461) that he is a "big fan" of peptides and has taken them himself, and that roughly 14 of the 19 peptides on the FDA's Category 2 list would be considered for a move back to Category 1. He says he expects a formal announcement "within a couple of weeks." These are remarks on a podcast, not an FDA action: no rule changed on this date, and Category 1 status would restore enforcement discretion rather than approve any peptide as a drug.
FDA removes 12 peptides from Category 2 and schedules the PCAC meetings
The FDA updates its Bulk Drug Substances Nominated for Use in Compounding list to remove 12 peptides from Category 2, effective within seven calendar days, because the original nominators withdrew their nominations. The 12 are BPC-157, TB-500, KPV, MOTS-c, emideltide (DSIP), Semax, Epitalon, LL-37, GHK-Cu (injectable), dihexa, Melanotan II, and PEG-MGF. Kennedy calls it "long-overdue action to restore science, accountability and the rule of law." Note the gap between this and February: he floated roughly 14 substances on the podcast, and the action covers 12. The FDA simultaneously publishes a Federal Register notice scheduling PCAC meetings for July 23-24, 2026 and before the end of February 2027 to consider these substances for the 503A Bulks List.
Why leaving Category 2 did not make these peptides legal to compound
Removal from Category 2 is not the same as being added to the Section 503A Bulks List, and conflating the two is the most common error in coverage of this story. The FDA's position is explicit: removal from Category 2 does not by itself place a substance on the 503A Bulks List or into Category 1, and it does not make the substance eligible for compounding under section 503A. Enforcement discretion extends only to Category 1 substances. The 12 peptides sit outside both categories pending PCAC review and a subsequent FDA determination, so compounding pharmacies still cannot legally prepare them. The category designations are interim policy applied during review; the Bulks List is the formal mechanism, and reaching it requires notice-and-comment rulemaking.
FDA reconstitutes the PCAC roster before the peptide vote
Ahead of the July meeting the FDA overhauls the Pharmacy Compounding Advisory Committee roster, adding members with ties to the peptide industry, and adds further temporary academic voting members in the week of the meeting. The changes draw press scrutiny over potential conflicts of interest. The roster shift also highlights a split inside the administration: HHS Secretary Robert F. Kennedy Jr. has publicly argued for loosening restrictions on peptides, while the FDA's own review staff recommend against adding any of the seven substances to the 503A Bulks List.
PCAC reviews seven peptides for the 503A Bulks List
The FDA's Pharmacy Compounding Advisory Committee meets at the White Oak campus to consider whether seven peptides should be added to the Section 503A Bulk Drug Substances List. The committee convened as scheduled on July 23, taking BPC-157, TB-500, KPV, and MOTS-c on day one and emideltide (DSIP), Semax, and Epitalon on day two, discussing and voting on each substance in turn. FDA staff briefing documents recommend against inclusion for all seven, concluding that none satisfy the criteria in 21 CFR 216.23(c) and citing inadequate substance characterization, inconsistent naming conventions, missing quality data, insufficient or absent human clinical trial evidence, and safety flags including immunogenicity risk. The docket is FDA-2025-N-6895; the public comment window closed July 22. PCAC is an advisory body: its vote is a recommendation, not a binding decision, and FDA must still decide whether to accept it and proceed through formal rulemaking.
PCAC votes to recommend six of the seven peptides, against FDA staff advice
The committee recommended adding six substances to the Section 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. Emideltide (DSIP) was the single rejection, voted down 6 to 7, with the committee citing especially weak evidence: one patient case report in narcolepsy and two small uncontrolled studies in opioid withdrawal. Reported tallies are narrow. BPC-157 passed 8 to 6 with one abstention, and KPV is reported at the same 8-6-1 split; per-substance counts for TB-500, MOTS-c, Epitalon, and Semax were not published in the coverage reviewed here. The outcome runs against the FDA's own review staff, who had recommended against all seven on the grounds that they fail the 21 CFR 216.23(c) criteria, and who raised limited effectiveness evidence, the availability of approved alternatives, and, for KPV specifically, the absence of any human studies. This does not change what a compounding pharmacy may legally prepare today. The vote is a recommendation; FDA must review the record and public comments and then publish proposed rules for notice-and-comment, a process reported as taking up to a year and historically 12 to 24 months.
Second PCAC meeting to cover five more peptides
A further PCAC meeting is expected to address five additional peptides: LL-37, GHK-Cu, dihexa acetate, Melanotan II, and PEG-MGF. Formal rulemaking following any PCAC recommendation typically takes 12 to 24 months, so compounding status for these substances is unlikely to change quickly regardless of the committee's vote.
What this means for peptide users
The regulatory environment for peptides has tightened significantly since 2023. The FDA's Category 2 list now restricts compounding of most popular research peptides including BPC-157, TB-500, and several growth hormone secretagogues. Enforcement has escalated from warning letters to physical raids and criminal prosecutions with multi-million dollar forfeitures.
Secretary Kennedy's remarks on the Joe Rogan podcast on February 27, 2026 raised expectations that roughly 14 peptides would return to legal compounding. What actually followed was narrower. On April 15, 2026 the FDA removed 12 peptides from Category 2, and only because the original nominations were withdrawn. That is not the same as legalizing them. The FDA has been explicit that leaving Category 2 does not place a substance on the 503A Bulks List or into Category 1, and does not make it eligible for compounding under section 503A. Compounding pharmacies still cannot legally prepare these peptides today.
The Pharmacy Compounding Advisory Committee met on July 23-24, 2026 and voted to recommend six of the seven peptides for the Section 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. Emideltide (DSIP) was rejected, 6 to 7. The margins were narrow, with BPC-157 passing 8 to 6 and one abstention. The committee went against its own agency's review staff, who had recommended against all seven.
Nothing about legal compounding status changed on the day of the vote. This is the point most coverage blurs. A PCAC vote is advisory, not binding. The FDA must review the meeting record and public comments, then publish proposed rules for notice-and-comment, a process reported as taking up to a year and historically 12 to 24 months. Until a substance actually appears on the 503A Bulks List, a compounding pharmacy cannot legally prepare it, and a favorable advisory vote is not FDA approval of the substance for any use.
For current legal status of specific peptides, see individual peptide profiles or the peptide legal status guide.
The regulatory story is still being written. This timeline is a living document, updated as events unfold. Bookmark it — the next chapter may change everything.